EUVIMEDEUVIMED entdecken
Crossref

INVESTIGATING THE USE OF mPGES-1 INHIBITORS FOR THE TREATMENT OF ABDOMINAL AORTIC ANEURYSMS

Lauren M. Weaver

UKnowledge (University of Kentucky) · 01.05.2023

DOI: 10.13023/etd.2023.073 ↗

Kurz gefasst

Fachartikel in der Zeitschrift UKnowledge (University of Kentucky), erschienen am 01.05.2023. Verfasst von Lauren M. Weaver.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The cardiovascular field is still searching for a treatment for abdominal aortic aneurysms (AAA). This inflammatory disease is a deadly, permanent ballooning of the aortic artery. It often goes undiagnosed until a late stage where associated rupture has a high mortality rate. Surgery is the only option available to patients, but it is risky. There are currently no FDA-approved pharmacological treatments for AAA available. Historically, drugs that have been examined in interventional clinical trials for treatment of AAA were repurposed therapeutics. Novel treatments have been unable to reach the clinic, stalling out in pre-clinical studies. Exceedingly few murine studies have examined an intervention-based drug treatment in halting further growth of an established AAA despite interventional treatment being the therapeutic approach taken to treat AAA in a clinical setting. Overall, current research stresses the importance of both centralized antiinflammatory drug targets and rigor of translatability. Notably, microsomal prostaglandin E2 synthase-1 (mPGES-1) is recognized as a promising target for development of a next generation of anti-inflammatory drugs. To this end, it is suggested that inhibiting PGE2 formation with an mPGES-1 inhibitor is a leading drug target for AAA treatment. The Zhan Lab previously identified mPGES-1 inhibitors as potential anti-inflammatory drug candidates through two methods: structure-based rational design of novel small molecules and repurposing of FDA-approved drugs through computational modeling. The purpose of this work was to assess the capability of these lead mPGES-1 inhibitors to alter growth of AAA in the angiotensin (Ang)II-induced mouse model. We have shown successful implementation of a prevention-based treatment and more importantly, late-stage interventional drug treatment to modulate growth of AAA in this model. Additional studies supported the structure-activity relationship profile of our compounds and their potential translation into the clinical setting. Our results provide evidence supporting the use of mPGES-1 inhibitors as interventional treatment of AAA.

Schlagwörter

abdominal aortic aneurysmmPGES-1 inhibitorsmicrosomal prostaglandin E2 synthase-1prostaglandin E2anti-inflammatory drug targetsdrug repurposingstructure-activity relationshiptranslational drug development

Zitieren

APA

Weaver, L. M. (2023). INVESTIGATING THE USE OF mPGES-1 INHIBITORS FOR THE TREATMENT OF ABDOMINAL AORTIC ANEURYSMS. UKnowledge (University of Kentucky). https://doi.org/10.13023/etd.2023.073

Vancouver

Weaver LM. INVESTIGATING THE USE OF mPGES-1 INHIBITORS FOR THE TREATMENT OF ABDOMINAL AORTIC ANEURYSMS. UKnowledge (University of Kentucky). 2023. doi:10.13023/etd.2023.073

BibTeX
@article{Weaver2023,
  author = {Weaver, Lauren M.},
  title = {INVESTIGATING THE USE OF mPGES-1 INHIBITORS FOR THE TREATMENT OF ABDOMINAL AORTIC ANEURYSMS},
  journal = {UKnowledge (University of Kentucky)},
  year = {2023},
  doi = {10.13023/etd.2023.073}
}
Kostenlos starten →